Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass-2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Actelion
ClinicalTrials.gov Identifier:
NCT00303459
First received: March 16, 2006
Last updated: February 11, 2014
Last verified: February 2014

March 16, 2006
February 11, 2014
May 2006
September 2014   (final data collection date for primary outcome measure)
Time from baseline to first adjudicated morbidity/mortality event [ Time Frame: From baseline to end of study ] [ Designated as safety issue: No ]
  • Time from baseline to first adjudicated morbidity/mortality event
  • Change from baseline to Week 16 in 6 Minute Walk Test
Complete list of historical versions of study NCT00303459 on ClinicalTrials.gov Archive Site
  • Change from baseline to Week 16 in 6 minute walk test (6MWT) [ Time Frame: From baseline to week 16 ] [ Designated as safety issue: No ]
  • Change from baseline to Week 16 in WHO functional [ Time Frame: From baseline to Week 16 ] [ Designated as safety issue: No ]
  • Change from baseline to Week 16 in Borg dyspnea index [ Time Frame: From baseline to Week 16 ] [ Designated as safety issue: No ]
  • Change from baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) questionnaire [ Time Frame: From baseline to Week 16 ] [ Designated as safety issue: No ]
  • Patient Global Self Assessment at Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
  • Time to event for the first occurrence of Death, hospitalization for worsening or complication of PAH or initiation of IV prostanoids, Atrial Septostomy, or Lun Transplantation [ Time Frame: Baseline to end of study ] [ Designated as safety issue: No ]
  • Time to death of all causes from baseline to EOS [ Time Frame: Baseline to End of Study ] [ Designated as safety issue: No ]
  • Change from baseline to Week 16 in WHO functional class
  • Change from baseline to Week 16 in Borg dyspnea index
  • Change from baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) questionnaire
  • Patient Global Self Assessment at Week 16
  • Time to event for the first occurrence of hospitalization for worsening or complication of PAH or initiation of I.V. prostanoids, atrial septostomy, lung transplantation or death from baseline to End Of Study
  • Time to death of all causes from baseline to End of Study
Not Provided
Not Provided
 
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study

COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized.

The study continued until the predefined target number of morbidity/mortality events was reached.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pulmonary Arterial Hypertension
  • Drug: bosentan
    bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
  • Drug: placebo
    Matching bosentan placebo/b.i.d.
  • Experimental: A
    Bosentan
    Intervention: Drug: bosentan
  • Placebo Comparator: B
    Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
334
December 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed informed consent prior to initiation of any study-mandated procedure
  2. Males or females >=12 years of age (except for countries where this age limit is contrary to specific regulatory requirements).

    - Women of childbearing potential must have a negative pretreatment pregnancy test and must use a reliable method of contraception during study treatment and for at least 3 months after study treatment termination.

    ·Reliable methods of contraception are:

    O Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.

    O Intrauterine devices. O Oral, transdermal, injectable or implantable contraceptives only in combination with a barrier method.

    • Hormone-based contraceptives alone, regardless of the route of administration, are not considered as reliable methods of contraception.
    • Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.

      • Women not of childbearing potential are defined as postmenopausal (i.e., amenorrhea for at least 1 year), or documented surgically or naturally sterile.
  3. Patients with symptomatic PAH
  4. Patients with the following types of PAH belonging to WHO Group I:

    • Idiopathic (IPAH)
    • Familial (FPAH)
    • Associated with (APAH):

      i. Collagen vascular disease with normal left ventricular function (ejection fraction (EF) > 50%) ii. Congenital systemic-to-pulmonary shunts at least 2 years post surgical repair iii. Drugs and toxins

  5. PAH diagnosed by right heart catheter showing:

    • Mean pulmonary arterial pressure (mPAP) >= 25 mm Hg AND
    • Pulmonary capillary wedge pressure (PCWP) =< 15 mm Hg or left ventricular end diastolic pressure (LVEDP) =< 15 mmHg If both PCWP and LVEDP are available then the LVEDP value is retained for inclusion.
  6. Treatment with a stable dose of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to randomization (no sildenafil dosage adjustment should occur in this period) 7)150 m =< 6MWT =< 480 m, documented by 2 tests with second 6MWT within 15% of first 6MWT distance or a third test required

Exclusion Criteria :

  1. PAH belonging to WHO group II-V
  2. PAH associated with portal hypertension and HIV infection
  3. PAH associated with thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders and splenectomy
  4. PAH associated with significant venous or capillary involvement (PCWP > 15 mmHg): pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis
  5. Persistent pulmonary hypertension of the newborn
  6. Significant valvular disease with valvular lesions to be excluded by echocardiogram within 2 years prior to randomization (i.e. patients with tricuspid or pulmonary insufficiency secondary to PAH can be included)
  7. Restrictive lung disease: total lung capacity (TLC) < 60% of normal predicted value (see Appendix 3)
  8. Obstructive lung disease: forced expiratory volume/forced vital capacity (FEV1/FVC) < 0.5
  9. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
  10. Known HIV infection
  11. Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements or that may interfere with the safety or the evaluation of the study, such as chronic infection, chronic renal failure etc.
  12. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
  13. Pregnancy or breast-feeding
  14. Condition that prevents compliance with the protocol or adherence to therapy
  15. Systolic blood pressure < 85 mmHg
  16. Body weight < 40 kg
  17. Hemoglobin <75% of the lower limit of the normal range
  18. Aspartate aminotransferase (AST) and/or alanine aminotransferase ALT > 1.5 times the upper limit of normal ranges
  19. Known hypersensitivity or history of drug-related adverse events with bosentan (e.g. increase in liver function test results [LFTs]), or any of the excipients of its formulation
  20. Receipt of an investigational product other than sildenafil within 3 months before start of study treatment
  21. Treatment with endothelin receptor antagonists (ERAs), prostanoids or phosphodiesterase (PDE) 5 inhibitors other than sildenafil within 3 months prior to randomization
  22. Concomitant systemic treatment within 1 week prior to randomization with

    • calcineurin inhibitors (e.g., cyclosporine A and tacrolimus), sirolimus and everolimus
    • glibenclamide (glyburide)
    • both CYP2C9 and CYP3A4 (e.g., fluconazole, amiodarone, voriconazole)
    • combination of drugs that inhibit CYP2C9 and CYP3A4
  23. Treatment with nitrates and alpha-blockers at time of randomization
  24. In the opinion of the investigator - patients in need for treatment with any prostanoid up to Visit 4
  25. Significant left ventricular dysfunction
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Brazil,   Denmark,   Germany,   Greece,   Portugal,   Saudi Arabia,   Slovakia,   Spain,   Sweden,   United Kingdom
 
NCT00303459
AC-052-414, COMPASS-2
Yes
Actelion
Actelion
Not Provided
Not Provided
Actelion
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP